[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
Zidek
Walter
W
Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin.
D017311:Amlodipine / Q000009:adverse effects / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control*; D002423:Cause of Death; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014633:Valine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000068756:Valsartan
D047228:Angiotensin II Type 1 Receptor Blockers; D002121:Calcium Channel Blockers; D013777:Tetrazoles; D017311:Amlodipine; D000068756:Valsartan; D014633:Valine